Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe

Guidelines recommend that proton pump inhibitor-based triple regimens with clarithromycin not be used for Helicobacter pylori infection in areas where clarithromycin resistance is ≥15%, or in patients with prior macrolide use. Up-to-date information on local resistance patterns is limited, especiall...

Descripción completa

Detalles Bibliográficos
Autores principales: Mégraud, Francis, Graham, David Y., Howden, Colin W., Trevino, Ernest, Weissfeld, Alice, Hunt, Barbara, Smith, Neila, Leifke, Eckhard, Chey, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889195/
https://www.ncbi.nlm.nih.gov/pubmed/36191284
http://dx.doi.org/10.14309/ajg.0000000000002045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889195/
https://www.ncbi.nlm.nih.gov/pubmed/36191284
http://dx.doi.org/10.14309/ajg.0000000000002045

Ejemplares similares